# US 2022/0024888 A1 · Crystalline ppar-delta agonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0024888 A1
- Document ID: US20220024888A1
- Status: Published application
- Kind: A1
- Application number: 17/381,005
- Filed: 2021-07-20
- Published: 2022-01-27
- Earliest claimed: 2020-07-22
- Assignees: Reneo Pharmaceuticals, Inc.
- Applicants: Reneo Pharmaceuticals, Inc.
- Inventors: Susana DEL RIO GANCEDO; Osama SULEIMAN; Emma SHARP; Cristina BALOGH; Rachael LEE; Julie MACRAE; Neil FEEDER
- Web page: https://patentgrep.com/patent/US20220024888A1

## CPC

- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4866: {Organic macromolecular compounds}
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

## Claims

### Claim 1

Crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate (Compound II), wherein crystalline Compound II is crystalline Form 1, characterized as having:
(a) an XRPD pattern as shown in FIG. 1;
(b) an XRPD pattern with peaks at about 2.8_° 2-Theta, about 7.2° 2-Theta, about 13.4° 2-Theta, about 17.8° 2-Theta, about 19.7° 2-Theta, about 19.9° 2-Theta, and about 20.6° 2-Theta as measured using Cu Kα radiation;
(c) a DSC thermogram as shown in FIG. 2;
(d) a DSC thermogram with an endotherm having onset at about 179.5° C. and peak at about 181.6° C.;
(e) a TGA pattern as shown in FIG. 3;
(f) a TGA pattern with a 0.1% w/w loss from 25 to 60° C. and degradation onset at about 250° C.;
(g) an FTIR spectroscopy pattern as shown in FIG. 4;
(h) an FTIR spectroscopy pattern with peaks at about 103 cm−1, about 838 cm−1, about 1220 cm−1, about 1504 cm−1, and about 1612 cm−1;
(i) a Raman spectroscopy pattern as shown in FIG. 5;
(j) a Raman spectroscopy pattern with peaks at about 103 cm−1, about 126 cm−1, about 810 cm−1, about 1158 cm−1, about 1238 cm−1, about 1604 cm−1, and about 1629 cm−1;
(k) unit cell parameters equal to the following at 100 K:
Crystal System
Monoclinic
Space Group
P2/c
a (Å)
31.581(3)
b (Å)
6.1180(4)
c (Å)
27.2046(18)
α°
90
β°
94.447(7)
γ°
90
V (Å3)
5240.4(7)
Z
8
Calculated Density
1.363
(Mg/m3)
Absorption
0.937
coefficient (mm−1)
F(000)
2256
or
(l) combinations thereof.

### Claim 2

Crystalline Form 1 of sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate (Compound II) characterized as having:
an XRPD pattern as shown in FIG. 1.

### Claim 3

Crystalline Form 1 of sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate (Compound II) characterized as having:
an XRPD pattern with peaks at about 2.8° 2-Theta, about 7.2° 2-Theta, about 13.4° 2-Theta, about 17.8° 2-Theta, about 19.7° 2-Theta, about 19.9° 2-Theta, and about 20.6° 2-Theta as measured using Cu Kα radiation.

### Claim 4 (depends on 1)

The crystalline Compound II of claim 1, characterized as having:
an XRPD pattern as shown in FIG. 1; or
an XRPD pattern with peaks at about 2.80° 2-Theta, about 7.2° 2-Theta, about 13.4° 2-Theta, about 17.8° 2-Theta, about 19.7° 2-Theta, about 19.9° 2-Theta, and about 20.6° 2-Theta as measured using Cu Kα radiation.

### Claim 5 (depends on 1)

The crystalline Compound II of claim 1, characterized as having:
a DSC thermogram as shown in FIG. 2; or
a DSC thermogram with an endotherm having onset at about 179.5° C. and peak at about 181.6° C.

### Claim 6 (depends on 1)

The crystalline Compound II of claim 1, characterized as having:
a TGA pattern as shown in FIG. 3; or
a TGA pattern with a 0.1% w/w loss from 25 to 60° C. and degradation onset at about 250° C.

### Claim 7 (depends on 1)

The crystalline Compound II of claim 1, is characterized as having:
an FTIR spectroscopy pattern as shown in FIG. 4; or
an FTIR spectroscopy pattern with peaks at about 103 cm−1, about 838 cm−1, about 1220 cm−1, about 1504 cm−1, and about 1612 cm−1.

### Claim 8 (depends on 1)

The crystalline Compound II of claim 1, characterized as having:
a Raman spectroscopy pattern as shown in FIG. 5; or
a Raman spectroscopy pattern with peaks at about 103 cm−1, about 126 cm−1, about 810 cm−1, about 1158 cm−1, about 1238 cm−1, about 1604 cm−1, and about 1629 cm−1.

### Claim 9 (depends on 1)

The crystalline Compound II of claim 1, characterized as having:
unit cell parameters equal to the following at 100 K:
Crystal System
Monoclinic
Space Group
P2/c
a (Å)
31.581(3)
b (Å)
6.1180(4)
c (Å)
27.2046(18)
α°
90
β°
94.447(7)
γ°
90
V (Å3)
5240.4(7)
Z
8
Calculated Density
1.363
(Mg/mw3)
Absorption
0.937
coefficient (mm−1)
F(000)
2256

### Claim 10 (depends on 1)

The crystalline Compound II of claim 1, wherein crystalline Compound II is unsolvated.

### Claim 11 (depends on 1)

The crystalline Compound II of claim 1, wherein crystalline Compound II is at least about 95% pure.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the crystalline Compound II of claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is formulated for administration to a mammal by oral administration.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is in the form of a solid form pharmaceutical composition.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the pharmaceutical composition is in the form of a tablet, a pill, or a capsule.

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, comprising about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, and about 400 mg of crystalline Compound II.

### Claim at position 17

-20. (canceled)
